TY - JOUR
T1 - Occurrence of infection following prostate biopsy procedures in Japan Japanese Research Group for Urinary Tract Infection (JRGU)-A multi-center retrospective study
AU - Togo, Yoshikazu
AU - Kubo, Tatsuhiko
AU - Taoka, Rikiya
AU - Hiyama, Yoshiki
AU - Uehara, Teruhisa
AU - Hashimoto, Jiroh
AU - Kurimura, Yuichiro
AU - Takahashi, Satoshi
AU - Tsukamoto, Taiji
AU - Miyazaki, Jun
AU - Nishiyama, Hiroyuki
AU - Kira, Shinichiro
AU - Kiyota, Hiroshi
AU - Yazawa, Satoshi
AU - Niwa, Naoya
AU - Hongo, Hiroshi
AU - Oya, Mototsugu
AU - Kato, Taku
AU - Yasuda, Mitsuru
AU - Deguchi, Takashi
AU - Ishikawa, Kiyohito
AU - Hoshinaga, Kiyotaka
AU - Matsumoto, Minori
AU - Shigemura, Katsumi
AU - Tanaka, Kazushi
AU - Arakawa, Soichi
AU - Fujisawa, Masato
AU - Wada, Koichiro
AU - Uehara, Shinya
AU - Watanabe, Toyohiko
AU - Kumon, Hiromi
AU - Kobayashi, Kanao
AU - Matsubara, Akio
AU - Matsumoto, Masahiro
AU - Sho, Takehiko
AU - Hamasuna, Ryoichi
AU - Matsumoto, Tetsuro
AU - Hayami, Hiroshi
AU - Nakagawa, Masayuki
AU - Yamamoto, Shingo
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2014/4
Y1 - 2014/4
N2 - We retrospectively investigated the incidence of genitourinary tract infection in 5895 patients who underwent transrectal and/or transperineal prostate biopsy procedure between January and December 2011 at 46 institutions belonging to Japanese Research Group for Urinary Tract Infection (JRGU). The total rate of genitourinary tract infection after prostate biopsy was 0.76%, while that following transrectal procedure was 0.83% and following transperineal procedure was 0.57%, which were not significantly different. In contrast, febrile infection associated with a fever (≥38 °C) occurred significantly more frequently after transrectal (0.71%) than transperineal (0.16%) approach (P = 0.04). Notably, in infectious cases, Escherichia coli was most frequently isolated. Of the 9 E. coli strains isolated by urine culture, 6 (66.7%) produced extended spectrum β-lactamase (ESBL) and 7 (77.8%) showed levofloxacin resistance. Similarly, of 6 E. coli strains isolated by blood culture, 4 (66.7%) produced ESBL and 6 (100%) showed levofloxacin resistance. When the efficacy of antimicrobial prophylaxis (AMP) with levofloxacin for the patients undergoing transrectal or transperineal biopsy was compared between a single dose (500 mg) and that given for 2 or more days, no significant difference was observed for the rate of infection (transrectal: 0.82% vs. 1.04%, p = 0.94; transperineal: 0.30% vs. 0.46%, p = 0.68).
AB - We retrospectively investigated the incidence of genitourinary tract infection in 5895 patients who underwent transrectal and/or transperineal prostate biopsy procedure between January and December 2011 at 46 institutions belonging to Japanese Research Group for Urinary Tract Infection (JRGU). The total rate of genitourinary tract infection after prostate biopsy was 0.76%, while that following transrectal procedure was 0.83% and following transperineal procedure was 0.57%, which were not significantly different. In contrast, febrile infection associated with a fever (≥38 °C) occurred significantly more frequently after transrectal (0.71%) than transperineal (0.16%) approach (P = 0.04). Notably, in infectious cases, Escherichia coli was most frequently isolated. Of the 9 E. coli strains isolated by urine culture, 6 (66.7%) produced extended spectrum β-lactamase (ESBL) and 7 (77.8%) showed levofloxacin resistance. Similarly, of 6 E. coli strains isolated by blood culture, 4 (66.7%) produced ESBL and 6 (100%) showed levofloxacin resistance. When the efficacy of antimicrobial prophylaxis (AMP) with levofloxacin for the patients undergoing transrectal or transperineal biopsy was compared between a single dose (500 mg) and that given for 2 or more days, no significant difference was observed for the rate of infection (transrectal: 0.82% vs. 1.04%, p = 0.94; transperineal: 0.30% vs. 0.46%, p = 0.68).
KW - Antimicrobial prophylaxis
KW - Genitourinary tract infection
KW - Prostate biopsy
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84903739464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903739464&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2013.10.003
DO - 10.1016/j.jiac.2013.10.003
M3 - Article
C2 - 24594451
AN - SCOPUS:84903739464
SN - 1341-321X
VL - 20
SP - 232
EP - 237
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 4
ER -